3. Leviq. https://www.leqvio.com/ Retrieved on 05, 04, 2023.4. Ballantyne, C. M. et al. Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial. J Am Coll Cardiol. Mar 06, 2023. Epublished DOI: 10.1016/j.jacc.2023.02.018 5. Goldstein...
DC371739是具有我国自主知识产权,由中国科学院上海药物研究所柳红、王逸平和蒋华良课题组联合研发的抗高血脂症化学1类新药。其并不直接作用于PCSK9,对LDLR的mRNA也无影响。通过抑制转录因子HNF-1α,剂量依赖地降低PCSK9和ANGPTL3的mRNA水平,从而下调了PCSK9蛋白和ANGPTL3蛋白表达,进而增加了LDLR蛋白表达和LPL活性,促进...
“We look forward to advancing this program into Phase 3 development in the second half of this year.” Additional data from the Phase 2b Study for MK-0616 (MK-0616-008) MK-0616-008(NCT05261126) was a randomized, double-blind, placebo-cont...